Pulmonary and systemic toxicity of bleomycin on severe combined immune deficiency mice

Experimental Lung Research

Volumn 34, Issue 1, 2008, Pages 1-17

  Miyazawa, Hiroshi ^a   Takiguchi, Yuichi ^a   Hiroshima, Kenzo ^a   Kurosu, Katsushi ^a   Tada, Yuji ^a   Kasahara, Yasunori ^a   Sakao, Seiichiro ^a   Tanabe, Nobuhiro ^a   Tatsumi, Koichiro ^a   Kuriyama, Takayuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Blyeomycin; Pulmonary injury; Severe combined immune deficiency

Indexed keywords

BCG VACCINE; BLEOMYCIN; HYDROXYPROLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CELL COUNT; CELL INFILTRATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGITIS; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; WILD TYPE;

ANIMALS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL MOVEMENT; ESOPHAGITIS; LUNG DISEASES; LYMPHOCYTES; MACROPHAGES; MICE; MICE, SCID;

EID: 38349144994     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140701807621     Document Type: Article

References (38)

1. Dorr RT: Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol. 1992;19: 3-8.
2. Hecht SM: Bleomycin: new perspectives on the mechanism of action. J Natural Products. 2000;63: 158-168.
3. Abraham AT, Lin JJ, Newton DL, Rybak S, Hecht SM: RNA cleavage and inhibition of protein synthesis by bleomycin. Chem Biol. 2003;10: 45-52.
4. Sleijfer S: Bleomycin-induced pneumonitis. Chest. 2001;120: 617-624.
5. Chua F, Gauldie J, Laurent GJ: Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33: 9-13.
6. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170: 655-663.
7. Santana A, Saxena B, Noble NA, Gold LI, Marshall BC: Increased expression of transforming growth factor beta isoforms (beta 1, beta 2, beta 3) in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1995;13: 34-44.
8. Phan SH, Kunkel SL: Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992;18: 29-43.
9. Piguet PF, Rosen H, Vesin C, Grau GE: Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies. Am Rev Respir Dis. 1993;147: 435-441.
10. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N: Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol. 1997;16:91-101.
11. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N, Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N: Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest. 1999;104: 13-19.
12. Moseley PL, Hemken C, Hunninghake GW: Augmentation of fibroblast proliferation by bleomycin. J Clin Invest. 1986;78: 1150-1154.
13. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM: Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230: 943-945.
14. Schmidt JA, Mizel SB, Cohen D, Green I: Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol. 1982;128: 2177-2182.
15. Giri SN, Hyde DM, Hollinger MA: Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993;48: 959-966.
16. Bosma MJ, Carroll AM: The SCID mouse mutant: definition, characterization, and potential uses. Ann Rev Immunol. 1991;9: 323-350.
17. Blunt T, Finnie NJ, Taccioli GE, Smith GC, Demengeot J, Gottlieb TM, Mizuta R, Varghese AJ, Alt FW, Jeggo PA, Jackson JP: Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell. 1995;80: 813-823.
18. Fulop GM, Phillips RA: The scid mutation in mice causes a general defect in DNA repair. Nature. 1990;347: 479-482.
19. Biedermann KA, Sun JR, Giaccia AJ, Tosto LM, Brown JM: scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci U S A. 1991;88: 1394-1397.
20. Budach W, Hartford A, Gioioso D, Freeman J, Taghian A, Suit HD: Tumors arising in SCID mice share enhanced radiation sensitivity of SCID normal tissues. Cancer Res. 1992;52: 6292-6296.
21. Schuler W, Weiler IJ, Schuler A, Phillips RA, Rosenberg N, Mak TW, Kearney JF, Perry RP, Bosma MJ: Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell. 1986;46: 963-972.
22. Malynn BA, Blackwell TK, Fulop GM, Rathbun GA, Furley AJ, Ferrier P, Heinke LB, Phillips RA, Yancopoulos GD, Alt FW: The scid defect affects the final step of the immunoglobulin VDJ recombinase mechanism. Cell. 1988;54: 453-460.
23. Blackwell TK, Malynn BA, Pollock RR, Ferrier P, Covey LR, Fulop GM, Phillips RA, Yancopoulos GD, Alt FW: Isolation of scid pre-B cells that rearrange kappa light chain genes: formation of normal signal and abnormal coding joins. EMBO J. 1989;8: 735-742.
24. Tanaka T, Yamagami T, Oka Y, Nomura T, Sugiyama H: The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutation Res. 1993;288: 277-280.
25. Omori S, Takiguchi Y, Suda A, Sugimoto T, Miyazawa H, Takiguchi Y, Tanabe N, Tatsumi K, Kimura H, Pardington PE, Chen F, Chen DJ, Kuriyama T: Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair. 2002;1: 299-310.
26. Harrison JH Jr, Lazo JS: High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1987;243: 1185-1194.
27. Huszar G, Maiocco J, Naftolin F: Monitoring of collagen and collagen fragments in chromatography of protein mixtures. Anal Biochem. 1980;105: 424-429.
28. Shellito J, Sniezek M, Warnock M: Acquisition of peroxidase activity by rat alveolar macrophages during pulmonary inflammation. Am J Pathol. 1987; 129:567-577.
29. Okudela K, Ito T, Mitsui H, Hayashi H, Udaka N, Kanisawa M, Kitamura H: The role of p53 in bleomycin-induced DNA damage in the lung. A comparative study with the small intestine. Am J Pathol. 1999;155: 1341-1351.
30. Onuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA: Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer. 1974;33: 1230-1238.
31. Copur MS, Rose MG, Chu E: Miscellaneous chemotherapeutic agents. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer-Principles & Practice of Oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:4 16-422.
32. Sharma SK, MacLean JA, Pinto C, Kradin RL: The effect of an anti-CD3 monoclonal antibody on bleomycin-induced lymphokine production and lung injury. Am J Respir Crit Care Med. 1996;154: 193-200.
33. Schrier DJ, Phan SH: Modulation of bleomycin-induced pulmonary fibrosis in the BALB/c mouse by cyclophosphamide-sensitive T cells. Am J Pathol. 1984;116: 270-278.
34. Schrier DJ, Phan SH, McGarry BM: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis. 1983;127:614-617.
35. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 1979;120: 893-899.
36. Zhu J, Cohen DA, Goud SN, Kaplan AM: Contribution of T lymphocytes to the development of bleomycin-induced pulmonary fibrosis. Ann N Y Acad Sci. 1996;796: 194-202.
37. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM: T cell independence of bleomycin-induced pulmonary fibrosis. J Leuk Biol. 1999;65: 187-195.
38. Yamamoto T, Nishioka K: Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol. 2001;117: 999-1001.